

Succinate receptor GPR91 provides a direct link between high glucose levels and renin release in murine and rabbit kidney

Ildikó Toma, ... , Elliott Meer, János Peti-Peterdi

J Clin Invest. 2008;118(7):2526-2534. <https://doi.org/10.1172/JCI33293>.

Research Article

Nephrology

Diabetes mellitus is the most common and rapidly growing cause of end-stage renal disease in developed countries. A classic hallmark of early diabetes mellitus includes activation of the renin-angiotensin system (RAS), which may lead to hypertension and renal tissue injury, but the mechanism of RAS activation is elusive. Here we identified a paracrine signaling pathway in the kidney in which high levels of glucose directly triggered the release of the prohypertensive hormone renin. The signaling cascade involved the local accumulation of succinate and activation of the kidney-specific G protein–coupled metabolic receptor, GPR91, in the glomerular endothelium as observed in rat, mouse, and rabbit kidney sections. Elements of signal transduction included endothelial Ca^{2+} , the production of NO and prostaglandin (PGE_2), and their paracrine actions on adjacent renin-producing cells. This GPR91 signaling cascade may serve to modulate kidney function and help remove metabolic waste products through renal hyperfiltration, and it could also link metabolic diseases, such as diabetes, or metabolic syndrome with RAS overactivation, systemic hypertension, and organ injury.

Find the latest version:

<https://jci.me/33293/pdf>





Succinate receptor GPR91 provides a direct link between high glucose levels and renin release in murine and rabbit kidney

Ildikó Toma, Jung Julie Kang, Arnold Sipos, Sarah Vargas, Eric Bansal, Fiona Hanner, Elliott Meer, and János Peti-Peterdi

Department of Physiology and Biophysics and Department of Medicine, Zilkha Neurogenetic Institute, University of Southern California, Los Angeles, California, USA.

Diabetes mellitus is the most common and rapidly growing cause of end-stage renal disease in developed countries. A classic hallmark of early diabetes mellitus includes activation of the renin-angiotensin system (RAS), which may lead to hypertension and renal tissue injury, but the mechanism of RAS activation is elusive. Here we identified a paracrine signaling pathway in the kidney in which high levels of glucose directly triggered the release of the prohypertensive hormone renin. The signaling cascade involved the local accumulation of succinate and activation of the kidney-specific G protein-coupled metabolic receptor, GPR91, in the glomerular endothelium as observed in rat, mouse, and rabbit kidney sections. Elements of signal transduction included endothelial Ca^{2+} , the production of NO and prostaglandin (PGE_2), and their paracrine actions on adjacent renin-producing cells. This GPR91 signaling cascade may serve to modulate kidney function and help remove metabolic waste products through renal hyperfiltration, and it could also link metabolic diseases, such as diabetes, or metabolic syndrome with RAS overactivation, systemic hypertension, and organ injury.

Introduction

Renin-angiotensin system (RAS) activation in diabetes mellitus and the metabolic syndrome is a core abnormality that leads to many complications of the disease, including hypertension, proteinuria, and renal tissue injury (1, 2). It has been difficult to isolate acute and direct actions of hyperglycemia on glomerular structures from the systemic factors and complex intrarenal feedback mechanisms (3) that can indirectly activate the RAS. Therefore, the primary cause and exact mechanism of RAS activation in early diabetes is still elusive.

The G protein-coupled receptor, GPR91, which functions as a detector of cell metabolism (4, 5), may provide a new, direct link between hyperglycemia and RAS activation. Its ligand, the TCA cycle intermediate succinate (4), which is normally present in the mitochondria, can be released extracellularly if the local tissue energy supply and demand is out of balance (5). Succinate accumulation caused by restricted organ blood supply (local ischemia), GPR91 activation, and subsequent renin release has been recently implicated in the development of renovascular hypertension (4). GPR91 is present in many organs, including the kidney, liver, spleen, breast, and blood vessels, but it is expressed most abundantly in the kidney (4, 6). In the renal cortex, GPR91 was detected in various nephron segments and in the juxtaglomerular apparatus (JGA) (4), although the specific cellular localization has not been determined.

The JGA represents the major structural component of the RAS and is one of the most important regulatory sites of systemic blood pressure (7–9). Renin-producing juxtaglomerular (JG) cells, located in the wall of the terminal afferent arteriole, are key components of the JGA and receive numerous chemical signals from adjacent vas-

cular endothelial, smooth muscle, and tubular epithelial cells that precisely control the rate of renin release (8). Classic chemical mediators that stimulate renin release include prostaglandins (PGE_2 and PGI_2) and NO (8, 9). Release of renin from JG cells is considered the rate-limiting step of RAS activation, and it ultimately leads to the generation of Ang II, the main RAS product and the primary effector of pathology in diabetes (1). In addition, the renin precursor prorenin, which is also produced and released by JG cells, has been directly implicated in diabetic nephropathy (10).

Succinate has earlier been shown to cause renin release from the kidney (11). However, this effect has never been linked to the metabolism of high levels of glucose. Because of the newly discovered GPR91 receptor and its role in RAS activation (4), we hypothesized that it is a (patho)physiologically significant mediator by which high levels of glucose supply and metabolism at the onset of diabetes directly cause renin release through succinate and GPR91 signaling in the JGA.


Results

High glucose level directly triggers renin release in vitro. Direct and acute effects of high glucose levels on the JGA were studied free of systemic influences, using a well established in vitro approach (12, 13) that combines a JGA microperfusion model with fluorescence confocal imaging. Increasing glucose concentration of the afferent arteriole perfusate triggered renin release and vasodilatation of the afferent arteriole within a few minutes (Figure 1 and Supplemental Video 1; supplemental material available online with this article; doi:10.1172/JCI33293DS1). Within 30 minutes of high levels of glucose application, JGA granular content was reduced by $54 \pm 5\Delta\%$ (where $\Delta\%$ means the change in quinacrine fluorescence intensity [$F_0 - F$] normalized to the baseline [F_0]) compared with control basal release ($11 \pm 5\Delta\%$), and the afferent arteriole dilated significantly. These effects of high glucose level were endothelium dependent, since remov-

Nonstandard abbreviations used: [Ca^{2+}]_i, intracellular Ca^{2+} ; GENC, glomerular endothelial cell; JG, juxtaglomerular; JGA, JG apparatus; RAS, renin-angiotensin system; STZ, streptozotocin.

Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: *J. Clin. Invest.* 118:2526–2534 (2008). doi:10.1172/JCI33293.

**Figure 1**

Direct and acute effects of high glucose level on the JGA. (A and B) Real-time confocal fluorescence imaging of renin content (quinacrine, green) and vascular diameter (cell membranes are labeled with R-18, red) in the in vitro microperfused terminal afferent arteriole (AA) with attached glomerulus (G) freshly isolated from rabbit kidney. In response to increasing glucose concentration of the afferent arteriole perfusate from 5.5 mM (control, A) to 25.5 mM (high glucose level, B), a significant number of renin granules in JG cells (JG) released their fluorescent content and the afferent arteriole internal diameter (arrows) increased. Scale bar: 20 μ m. (C) Normalized reductions in quinacrine fluorescence (as an index of renin release) and increases in afferent arteriole diameter within 30 minutes of high glucose level (HG) application. Blockade of NO synthases (L-NAME; 1 mM) and cyclooxygenases ([I] indomethacin; 50 μ M) inhibited the effects of high glucose level, indicating involvement of NO and prostaglandins, respectively. Removing the endothelium (endo) or bath glucose had no effect, and equimolar mannitol caused only minor renin release. * $P < 0.01$; $n = 6$ each.

ing the endothelium of the afferent arteriole ($14 \pm 1\Delta\%$) or bath application of high glucose level ($6 \pm 7\Delta\%$) had no effect on renin release. The use of mannitol to control for the effect of osmolality resulted in only minor renin release ($19 \pm 4\Delta\%$). The actions of high glucose level most likely involved NO and prostaglandins, since both NO synthase and cyclooxygenase inhibition abolished the effects of application of high levels of glucose ($14 \pm 6\Delta\%$ and $13 \pm 2\Delta\%$ renin release, respectively). Similar effects were observed on the vascular tone.

Involvement of the TCA cycle intermediate succinate. Since it was established earlier that succinate causes renin release (11), we tested whether the mechanism of the high-level-of-glucose effect involves the TCA cycle. The effects of various TCA cycle inhibitors and intermediates were studied using the same experimental model as above. The strategy is summarized in Figure 2A, and the findings are shown in Figure 2, B–D. First, the addition of 5 mM succinate to the arteriolar perfusate triggered a robust renin release ($73 \pm 2\Delta\%$), confirming the earlier data (11). The effects of succinate and high glucose levels did not appear to be additive ($56 \pm 3\Delta\%$; Figure 2B). Then malonate, an inhibitor of the TCA cycle at the succinate dehydrogenase step (succinate degradation), was used. Malonate alone, in the presence of normal glucose (5.5 mM), caused significant renin release ($54 \pm 7\Delta\%$). Combining malonate with a high glucose level produced an augmented response ($77 \pm 2\Delta\%$). The effect of malonate was additive to that of succinate as well ($83 \pm 4\Delta\%$; Figure 2B). Fluorocitrate was next used to block the TCA cycle enzyme aconitase, which is essential for producing succinate. The addition of fluorocitrate alone had no effect on renin release ($11 \pm 2\Delta\%$), but it abolished the effects of high glucose level on renin release ($16 \pm 2\Delta\%$). In subsequent studies, the dose-response relationship among succinate or malonate and renin release was established (Figure 2C). The EC_{50} values for succinate and malonate were 335 and 367 μ M, respectively. Administration of α -ketoglutarate (5 mM), another intermediate between the citrate and succinate steps, had no effect (data not shown). Thus, Krebs-cycle intervention studies revealed

that renin release specifically occurred in the presence of succinate. Using real-time imaging, the time course of high glucose level- and succinate-induced renin release was established (Figure 2D). Succinate produced a more robust and rapid effect, consistent with the hypothesis that high glucose levels act through accumulating succinate levels. In addition to renin release, we observed substantial vasodilatation of the afferent arteriole within 3–4 minutes after treatment with high glucose levels.

Succinate levels in normal and diabetic kidney tissue and urine. To demonstrate local accumulation of succinate in the diabetic kidney tissue to levels that are consistent with GPR91 activation, we measured succinate in nondiabetic and diabetic kidney tissue and urine (Figure 3). In freshly harvested urine and whole kidney tissue samples of nondiabetic mice, the succinate concentration was 26 ± 7.0 and 10 ± 0.2 μ M, respectively. In contrast, 1–2 orders of magnitude higher levels were detected in samples from diabetic mice 1 week after streptozotocin (STZ) injection (168 ± 45 μ M in urine; 616 ± 62 μ M in tissue).

GPR91 specificity. Similar microperfusion experiments were performed using preparations dissected from $GPR91^{+/+}$ and $GPR91^{-/-}$ mouse kidneys. Increasing glucose content of the afferent arteriole perfusate from 5.5 to 25.5 mM greatly stimulated the rate of renin release in $GPR91^{+/+}$ mice, similar to that observed in rabbits (Figure 1C). Granular content was reduced by $44 \pm 3\Delta\%$ within 30 minutes (Figure 4). Importantly, high glucose level-induced renin release was diminished in $GPR91^{-/-}$ mice; granular content was reduced by only $16 \pm 3\Delta\%$. Interestingly, the magnitude of this response is comparable to what was obtained before using mannitol for the control of osmolality effect (Figure 1C). These data suggest that the effect of high glucose level on renin release has a minor hyperosmotic, but a very significant metabolic component. The succinate receptor GPR91 appears to be involved in the metabolic component, consistent with our main hypothesis that high glucose level triggers renin release through the accumulation of succinate and GPR91 signaling.

Localization of GPR91. Molecular and functional studies were performed to identify the cell type(s) expressing GPR91 and involved in the generation of the renin release signal. RT-PCR was performed to detect $GPR91$ mRNA in mouse whole kidney and in cell cultures of various JGA cell types (Figure 5A). Consistent with the role of the vascular endothelium in glucose-induced renin release (Figure 1C), expression of the succinate receptor GPR91 was found on the mRNA




Figure 2 Effects of TCA cycle intermediates and inhibitors on renin release. (A) Overview of the TCA cycle and sites of inhibition with fluorocitrate (F; 100 μM; blocks aconitase in step 2) and malonate (MAL; 1 mM; blocks succinate dehydrogenase in step 6). (B) Effects of TCA cycle inhibitors on renin release in presence of normal (5.5 mM when not indicated) or high glucose (25.5 mM), or succinate (SUCC, 5 mM) levels. C, control. **P* < 0.001, control vs. high glucose, high glucose plus succinate, succinate, and malonate. ***P* < 0.001 malonate alone vs. malonate plus high glucose, and malonate plus succinate. *n* = 6 each. (C) Dose-dependent effects of succinate and malonate on in vitro renin release. *n* = 6 measurements for each dose. (D) Representative recordings of changes in quinacrine fluorescence intensity (renin release) in control and in response to high glucose and succinate levels (black lines), and the time course of the high glucose level-induced afferent arteriole vasodilatation (gray line).

level in a recently established glomerular endothelial cell (GENC) line (14). In contrast, primary cultures of VSMCs and JG cells produced no signal (for confirmation of cell phenotypes see Supplemental Figure 1). Whole kidney tissue from *GPR91*^{+/+} and *GPR91*^{-/-} mice served as positive and negative controls. To determine the localization of GPR91 protein in the kidney and in cells of the JGA in particular, immunohistochemistry on rat (Figure 5, B–E), mouse, and rabbit (data not shown) kidney sections was performed using a recently produced, commercially available GPR91 polyclonal antibody. Vascular endothelial cells in the afferent arteriole and glomerulus, but not JG cells, were labeled positive for GPR91 (Figure 5B). Endothelial localization was confirmed by double labeling with the rat endothelial marker RECA-1 (Figure 5C). GPR91 and RECA-1 immunolabeling were localized to the same structures (Figure 5D). This is consistent with the RT-PCR data above (Figure 5A) and with our hypothesis that it is the vascular endothelium, rather than other JGA cells, that is capable of detecting extracellular succinate.


Additional functional studies tested whether GENCs that express GPR91, but not VSMCs and JG cells, produce elevations in cytosolic Ca²⁺ levels in response to the same TCA cycle inhibitors and inter-

mediates that were used with in vitro renin release measurements (Figure 2B). Figure 5F shows significant elevations in GENC intracellular Ca²⁺ [Ca²⁺]_i levels in response to high glucose level (605 ± 36 nM), succinate (549 ± 29 nM), and malonate (377 ± 22 nM) compared with [Ca²⁺]_i levels measured in presence of normal glucose (133 ± 14 nM). Fluorocitrate failed to increase GENC [Ca²⁺]_i levels (143 ± 11 nM) (Figure 5F). GENCs produced a substantial, dose-dependent Ca²⁺ signal when high levels of glucose or succinate were added to the superfusate, with an EC₅₀ value of 11 mM and 69 μM, respectively (Figure 5G). These data are consistent with the central role of succinate and the proposed Ca²⁺-coupled mechanism of GPR91 signaling (4). In addition, saturating doses of succinate did not cause [Ca²⁺]_i elevations in VSMCs, JG cells, or HEK cells (Figure 5H). Also, the succinate-induced response in GENCs was GPR91-specific, since silencing GPR91 with short, interfering RNAs (siRNA) produced no [Ca²⁺]_i response (Figure 5H). Evidence for effective silencing of GPR91 in cultured GENCs using siRNA can be found in Supplemental Figure 2.

Elements of the paracrine signal transduction cascade. Since endothelial cells are indispensable for high glucose level-induced renin release and are the only cell types in the terminal afferent arteriole to express GPR91, they appear to be key components of generating the renin release signal.

Fluorescence imaging studies in the microperfused JGA measured endothelial intracellular Ca²⁺ ([Ca²⁺]_i) changes and NO production (Figure 6, A–C). Increasing glucose concentration from 5.5 to 25.5 mM or the addition of 5 mM succinate to the arteriolar perfusate caused significant elevations in [Ca²⁺]_i and NO production in the vascular endothelium (Figure 6C). In addition, the effect of high glucose level was GPR91-dependent (Figure 6C). Since prostaglandins (PGE₂ and PGI₂) are classic mediators of renin release, further experiments tested if endothelial [Ca²⁺]_i elevations trigger not only NO but also PGE₂ production and release from GENCs (Figure 6D). As expected, GENCs released PGE₂ in response to succinate in a dose-dependent fashion with an EC₅₀ value of 214 μM. These chemical mediators, NO and PGE₂, are effective vasodilators and were most likely involved in the high glucose level-induced increase in afferent arteriole diameter observed simultaneously with renin release.

GPR91 signaling in the STZ model of type 1 diabetes in vivo. Whole animal studies were performed using *GPR91*^{+/+} and *GPR91*^{-/-} mice to evaluate the in vivo importance of GPR91 in renin signaling in diabetic and nondiabetic control animals using the STZ model of type 1 diabetes (STZ-diabetes). A multiphoton imaging approach



(15, 16) was used to directly visualize and quantify JGA renin granular content in the intact, living kidney (Figure 7, A–E). Nondiabetic *GPR91*^{-/-} mice had reduced JGA renin granular content compared with *GPR91*^{+/+} littermates (Figure 7, A, B, and E), although total renal renin content was not altered based on whole kidney immunoblotting (Figure 7, F and G). In *GPR91*^{+/+} mice, the STZ-diabetes caused a 3.5-fold increase in total renin (Figure 7, F and G) and a less pronounced but still significant increase in JGA renin granular content (Figure 7, C–E). Importantly, both total and JGA renin were significantly reduced in *GPR91*^{-/-} littermates with STZ-diabetes (Figure 7, E and G).

As an important hallmark and in vivo parameter of diabetes, we measured prorenin levels in kidney tissue and plasma samples of control and diabetic *GPR91*^{+/+} and *GPR91*^{-/-} mice (Figure 8). Diabetes induced a robust, more than 20-fold increase in kidney tissue and plasma prorenin contents in *GPR91*^{+/+} mice. In contrast, the increases in kidney tissue and plasma prorenin were significantly blunted in *GPR91*^{-/-} mice (Figure 8). These results clearly suggest the involvement of GPR91 in the (patho)physiological control of renal renin and prorenin synthesis and release in vivo.

Discussion

The present work identified succinate as an important element of the diabetic milieu that links high level of glucose supply and metabolism with RAS activation. High glucose level, through the TCA cycle intermediate succinate and the activation of its receptor GPR91, acts directly and acutely on the JGA and triggers renin release, the rate-limiting step of RAS activation. The central role of RAS in the pathogenesis of diabetic nephropathy has been established in the past several decades; however, a unifying mechanism of RAS activation in both type 1 and type 2 diabetes has been sorely lacking (2). The presently identified GPR91-dependent paracrine JGA-signaling cascade provides, for what we believe to be the first time, a direct mechanism for the local intrarenal activation of RAS in diabetes.

Normally, succinate is present in mitochondria, but it is also found in the systemic circulation in the 1- to 20-µM range (17). However, succinate can accumulate extracellularly in peripheral tissues in certain pathophysiological states when energy and oxygen supply/demand are out of balance (5). Although, it is not feasible to measure succinate levels in the JGA interstitium, conditions of the renal cortical environment seem to be favorable for local succinate accumulation. In spite of high cortical blood flow, significant shunting of oxygen within the cortical, preglomerular vasculature between interlobular arteries and veins results in low cortical pO₂ values in the range of 40 mmHg (18). The nonlinear nature of single nephron blood flow (19) is another possible contributing factor. Hyperglycemia is associated with further, marked reductions in renal oxygen tension and mito-

Figure 3

Succinate accumulation in diabetic kidney tissue and urine. An enzyme assay and freshly harvested urine and whole kidney homogenates were used to estimate succinate accumulation in control ($n = 5$) versus diabetic (DM; 1 week after STZ treatment; $n = 6$) *GPR91* WT mouse kidneys. Individual samples were measured in triplicates and averaged. * $P < 0.001$ control vs. diabetic.

chondrial respiration (20). Therefore (juxta)glomerular endothelial cells appear to be well suited and strategically positioned to sense the local accumulation of succinate. Consistent with this, we measured 1–2 orders of magnitude higher levels of succinate in the urine and kidney homogenates of diabetic animals 1 week after STZ injection compared with controls (Figure 3). In addition, a recent report found similar but less pronounced changes in serum succinate levels in diabetes (21), further supporting the local, intrarenal accumulation of succinate. The present findings (Figure 5, F and G, and Figure 6, A and C) that GENCs, either in culture or in the native tissue, respond to high glucose level with dose-dependent, significant elevations in $[Ca^{2+}]_i$, a response which is GPR91 specific, further support local succinate accumulation. Although GENCs alone appear to be capable of generating extracellular succinate in amounts that trigger GPR91, other JGA cell types most likely contribute to the local succinate accumulation. GPR91 localization studies on both the mRNA and protein level (Figure 5) identified the (juxta)glomerular endothelium as one possible sensor of local succinate. Succinate-induced GPR91 signaling in GENCs, either cultured (Figure 5F) or freshly dissected (Figure 6C), involved elevations in $[Ca^{2+}]_i$ and the production and release of NO and PGE₂ (Figures 5 and 6), well established vasodilators and classic mediators of renin release from adjacent JG cells (8, 9). Although high, saturating concentrations of succinate (5 mM) were used in some studies, the low EC₅₀ values resulting from the succinate effect on GENC $[Ca^{2+}]_i$ (69 µM), PGE₂ production (214 µM), and renin release (335 µM) suggest that near physiological succinate levels can activate GPR91. The relatively higher EC₅₀ values established




Figure 4

High glucose level-induced renin release in *GPR91*^{+/+} and *GPR91*^{-/-} mice. Effects of high glucose level (25.5 mM) on renin release, measured by the reduction in quinacrine fluorescence. Hyperosmotic control using mannitol is also shown (same data as in Figure 1C). C, control baseline renin release. *GPR91*^{+/+} (WT, $n = 6$) and *GPR91*^{-/-} (KO, $n = 4$) mice were used. * $P < 0.001$, control vs. high glucose lumen (rabbit, mouse).




Figure 5


Localization of GPR91 in GENCs. (A) Representative RT-PCR demonstrating the presence/absence of GPR91 in various mouse kidney cell types. C, control mix with no cDNA; WK, whole kidney from WT *GPR91*^{+/+} or KO *GPR91*^{-/-} mice. Same results were obtained in *n* = 6 different samples each. JGC, renin-producing JG cells. (B–E) Localization of GPR91 protein in rat kidney with immunohistochemistry. (B) Strong GPR91 labeling (red) was found in vascular endothelial cells, in both terminal afferent arteriole (Aff. art.) and glomerulus. One region of the glomerulus (indicated by a rectangle) is magnified in C and D for high-resolution colocalization studies. (C) Double labeling for rat endothelial cell marker RECA-1 (green) identified the endothelium of intraglomerular capillary loops (cl). (D) Overlay of GPR91 (red) and RECA-1 (green) images shows colocalization (yellow) of the 2 proteins in the same structures. DIC background is merged with fluorescence to show glomerular morphology. (E) Negative control using no GPR91 primary antibody. Nuclei are blue. Scale bar: 10 μ m (B–E). (F) Elevations in GENC $[Ca^{2+}]_i$ levels from baseline (under normal glucose [NG], 5.5 mM) in response to high glucose level (25.5 mM) and TCA cycle inhibitors and intermediates. Succinate, 5 mM; malonate, 1 mM; fluorocitrate, 100 μ M. **P* < 0.001, compared with NG; *n* = 9 each. (G) Dose-response relationship of high glucose level- and succinate-induced elevations in GENC Ca^{2+} levels; *n* = 6 each. *F/F*₀, fluorescence (*F*) normalized to baseline (*F*₀). (H) Cell- and GPR91-specificity of the succinate-induced $[Ca^{2+}]_i$ response. HEK cells were used for biosensor experiments (see below). **P* < 0.001, compared with baseline; *n* = 6 each. Cells were grown on coverslips to near confluency, loaded with Ca^{2+} sensitive fluorescent dye fura-2, and $[Ca^{2+}]_i$ was measured using a cuvette-based spectrofluorometer (Quantmaster-8; Photon Technology Inc.).

with the PGE₂ biosensor assay and the in vitro renin release model are not unexpected, since these are more downstream, complex, and highly regulated mechanisms; therefore, they are somewhat less sensitive. The involvement of NO and prostaglandins in high glucose level-induced (succinate-induced) renin release was also supported by in vitro microperfusion data (Figure 1C), using blockers of the synthetic enzymes NOS and cyclooxygenase (COX). Nonselective inhibitors were used, since many isoforms of NOS (NOSI–III) (22, 23) and COX (COX-1 and -2) (24, 25) are present in the JGA. Importantly, NOSIII (endothelial NOS) and COX-2 are upregulated in diabetes (23, 25). Localization of GPR91 in the proximal and distal nephron (4) suggests other potential sites of succinate detection in the kidney and warrants further studies. It should be noted that numerous, well established, and ubiquitous dicarboxylate carriers and organic anion transporters are expressed in high amounts in the kidney, both in mitochondrial and cell membranes that transport succinate along its concentration gradient and that may be involved in extracellular succinate accumulation (26–28).

Inhibition of the Krebs cycle before or after the succinate step caused marked but differing changes in renin release (Figure 2, A–C). At normal glucose levels, malonate, an inhibitor of the succinate dehydrogenase complex (29), caused robust renin release, the effect

of which was markedly enhanced in the presence of high glucose level or succinate. In contrast, fluorocitrate, an inhibitor of aconitase (30, 31) and succinate production, blocked renin release induced by high glucose level. Consistent with these data and Ca^{2+} -mediated GPR91 signaling, differing GENC Ca^{2+} level changes were observed with malonate and fluorocitrate (Figure 5F). The opposite effects of these metabolic inhibitors suggest the specific role of succinate and exclude the possibility of tissue injury. Oxygen consumption and ATP production in the kidney remain constant after malonate and fluorocitrate administration in vivo (29, 31) due to the use of alternative substrates (glutamine). Also, the partial renin-releasing effect of osmolytes (controlled with mannitol) is consistent with a recent report (32) that acute increases in osmolality trigger renin release.

Reduced JGA renin content in control, nondiabetic *GPR91*^{-/-} mice (Figure 7, B and E) suggests that succinate signaling through GPR91 is a physiological mechanism to control RAS activity, in addition to its potential role in diabetic pathology. Since the present in vivo studies focused on the early phase of diabetes, it will be interesting to study in future work the chronic phase of the disease and the role of GPR91 in the development of in vivo diabetic renal complications, such as proteinuria and hypertension. It should be noted, however, that further studies on the role of GPR91 in blood pressure control

**Figure 6**

GPR91 signaling in the vascular endothelium. Succinate- and GPR91-induced endothelial cytosolic Ca²⁺ [Ca²⁺]_i signaling and NO production were studied using the microperfused mouse afferent arteriole–attached glomerulus preparation and confocal fluorescence microscopy with fluo-4/fura red ratio-metric Ca²⁺ (A) and DAF-FM imaging (B), respectively. Arrows point at glomerulus and afferent arteriole endothelial cells in situ. Scale bar: 20 μm. (C) Summary of the high glucose– (25.5 mM) and succinate– (5 mM) induced normalized changes in endothelial [Ca²⁺]_i and NO production in WT GPR91^{+/+} or KO GPR91^{-/-} kidney tissue. *P < 0.05, WT (+/+) vs. KO (-/-); n = 6 each. (D) Dose-response relationship of succinate-induced elevations in PGE₂ production and release from cultured GENCs, measured using a PGE₂ biosensor. Specially engineered biosensor cells, HEK293 cells, expressing the Ca²⁺-coupled PGE₂ receptor EP1 were loaded with fluo-4 and positioned next to GENCs in culture. Effects of succinate on GENC PGE₂ production were measured based on the biosensor cell Ca²⁺ signal, since upon PGE₂-binding these biosensor cells produce a Ca²⁺ response detected by fluorescence imaging. The cyclooxygenase inhibitor indomethacin (50 μM) and EP1 receptor blocker SC-51322 (10 μM) in presence of 5-mM succinate both served as negative controls for PGE₂ specificity. Normalized changes in HEK293-EP1 biosensor cell fluo-4 intensity are shown and served as an index of PGE₂ release. n = 6 for each dose.

in diabetes are hampered by the lack of good mouse models of diabetic nephropathy (2, 33). Mice are resistant to a number of renal and systemic complications of diabetes, such as the lack of diabetes-induced hypertension (2, 33). Nevertheless, hypertension and systemic RAS activation may not be as central to diabetes as previously thought (1, 2), since the identification of the prorenin receptor in the kidney (34) and its local signaling provides an Ang II-independent alternative in the pathogenesis of diabetic renal damage (35, 36). The possible involvement of prorenin in GPR91-mediated renin granule exocytosis in diabetes (Figure 8) is intriguing and consistent with the importance of the prorenin receptor and requires further study. Nevertheless, the present studies established that the elevation in plasma and kidney tissue prorenin, at least one in vivo parameter that is classic in diabetes, is GPR91-dependent. In addition to triggering renin release, GPR91-mediated NO and PGE₂ production in the JGA could be an important causative mechanism of vascular smooth muscle and mesangial relaxation (Figure 1C and Figure 2D), resulting in glomerular hyperfiltration, another hallmark of early diabetes (1–3).

In summary, we identified a paracrine signaling mechanism within the JGA initiated by high glucose levels (such as those characteristic of diabetes), which directly activates renin synthesis and release and causes vasodilatation of the afferent arteriole. This signaling mechanism involves the (juxta)glomerular endothelium, a sensor of accumulating succinate levels in hyperglycemia through what we believe to be a novel metabolic receptor GPR91, Ca²⁺-coupled generation and release of endothelial NO and prostaglandins (at least PGE₂), and their actions on adjacent JG renin-producing cells. We believe GPR91 is a new potential therapeutic target to prevent renal complications of diabetes.

Methods

Animals. All experiments were performed with the use of protocols approved by the Institutional Animal Care and Use Committee at the University of Southern California (USC). Female New Zealand rabbits (about 500 g) were purchased from Irish farms. Breeding pairs of GPR91^{-/-} mice (C57BL/6 background) were provided by Amgen and were bred at USC. Animals were housed in a temperature-controlled room under a 12-hour light-dark cycle with water and standard chow available ad libitum. In some mice, the STZ model of type 1 diabetes was used as described before (15, 33). Briefly, diabetes was induced by daily i.p. STZ (50 mg/kg) injections for 4 days. Blood was collected from tail vein, and blood glucose levels were measured with test strips (Freestyle Blood Glucose Monitoring System; Abbott Laboratories) to confirm the successful induction of diabetes (blood glucose levels greater than 400 mg/dl). Animals were studied within 4 weeks after STZ injection, during the early phase of diabetes.

Genotyping of mice. Mice were characterized by PCR using genomic DNA extracted from tail biopsies. DNA was digested with the REExtract-N-Amp Tissue PCR Kit (Sigma-Aldrich). Routine genotyping by PCR was performed using the following primers: Neo3A (5'-GCAGCGCATGCCCTTC-TATC-3'), GPR91^{-/-} reverse (5'-GCTGCCTTCTGATTATGTGG-3'), and GPR91^{-/-} forward (5'-GTCGCTCTGGGCCTTAGTACC-3').

In vitro microperfusion. A superficial afferent arteriole with its glomerulus was microdissected from freshly harvested kidney slices. The afferent arteriole was cannulated and perfused using a method similar to those described previously (37). Briefly, dissection media were prepared from DMEM mixture F-12 (Sigma-Aldrich). Fetal bovine serum (Hyclone) was added at a final concentration of 3%. Vessel perfusion and bath fluid was a modified Krebs-Ringer–HCO₃ buffer containing 115 mM NaCl, 25 mM NaHCO₃, 0.96 mM NaH₂PO₄, 0.24 mM Na₂HPO₄, 5 mM KCl, 1.2 mM




Figure 7


Renin granular content in *GPR91*^{+/+} and *GPR91*^{-/-} mice in vivo. (A and B) Representative multiphoton fluorescence images of JGA renin content (green) in nondiabetic (A and B) and diabetic (C and D) *GPR91*^{+/+} (A and C) and *GPR91*^{-/-} (B and D) mouse kidneys. The intravascular space (plasma) was labeled using a 70-kDa dextran rhodamine conjugate (red). Scale bar: 20 μm. (E) Summary of changes in JGA renin content in control and in the STZ model of type 1 diabetes (STZ-diabetic; DM) *GPR91*^{+/+} and *GPR91*^{-/-} mice. JGA renin content was calculated based on measuring the area of quinacrine fluorescence (μm²). **P* < 0.05, C vs. DM *GPR91*^{+/+}; §*P* < 0.05, C *GPR91*^{+/+} vs. C *GPR91*^{-/-}; #*P* < 0.05, DM *GPR91*^{+/+} vs. DM *GPR91*^{-/-} (*n* = 4 each). (F) Renin immunoblot (green) using control and STZ-diabetic *GPR91*^{+/+} and *GPR91*^{-/-} mouse whole kidney. Four samples are shown for each group. β-actin (red) served as loading control. (G) Summary of changes in whole kidney renin content based on renin immunoblot densitometry. **P* < 0.05 C vs. DM *GPR91*^{+/+}; #*P* < 0.05 DM *GPR91*^{+/+} vs. DM *GPR91*^{-/-} (*n* = 4 each).

MgSO₄, 2 mM CaCl₂, 5.5 mM D-glucose and 100 μM L-arginine. The solutions were aerated with 95% O₂ and 5% CO₂ for 45 minutes, and their pH was adjusted to 7.4. Each preparation was transferred to a thermo-regulated Lucite chamber mounted on the Leica inverted microscope. The preparation was kept in the dissection solution, and also, temperature was kept at 4°C until cannulation of the arteriole was completed and then was gradually raised to 37°C for the remainder of the experiment. In some experiments, the endothelium was mechanically removed from the vessel wall with the help of the perfusion pipette and by perfusing the control solution under the endothelium (between the endothelium and smooth muscle). This maneuver resulted in the detachment of the endothelial layer from the smooth muscle-JG cells. The bath was continuously aerated with 95% O₂ and 5% CO₂. The acidotropic fluorophore quinacrine (Sigma-Aldrich), which is an intravital fluorescent dye selective for dense-core secretory granules, was used for labeling the renin granules (12, 13, 15). The membrane staining octadecyl rhodamine B chloride R18 and the nuclear stain Hoechst 33342 were used to visualize the glomerulus with its attached afferent arteriole. For ratiometric Ca²⁺ imaging, the fluo-4/fura red pair was used and calibrated as described before (37). DAF-FM was used to monitor changes in NO production as described (38). All fluorophores were from Invitrogen.

Multiphoton fluorescence microscopy. Preparations were visualized using a 2-photon laser scanning fluorescence microscope (TCS SP2 AOBs MP confocal microscope system; Leica-Microsystems). A Leica DM IRE2 inverted microscope was powered by a wideband, fully automated, infrared (710–920 nm), combined photo-diode pump laser and mode-locked titanium:sapphire laser (Mai-Tai; Spectra-Physics) for multiphoton excitation and/or by red (HeNe 633 nm/10 mW), orange (HeNe 594 nm/2 mW), green (HeNe 543 nm/1.2 mW) and blue (Ar 458 nm/5 mW; 476 nm/5 mW; 488 nm/20 mW; 514 nm/20 mW) lasers for conventional, 1-photon-excitation confocal microscopy. Images were collected in time-series (xyt) and analyzed with Leica LCS imaging software.

Cell culture. TsA58 immorto mice GENCs (a generous gift from N. Akis, Halic University, Istanbul, Turkey) have been characterized before (14) and were grown to confluence in 10% DMEM, 25 mM HEPES, 9 mM NaHCO₃, 7.5% new born calf serum (Gibco), and 1% penicillin/streptomycin in a humidified (95% O₂ and 5% CO₂) incubator at 37°C. Afferent arteriolar VSMCs and JG renin-producing cells were freshly isolated from C57BL/6 mouse kidneys using available techniques (39–41).

Succinate assay. Kidney tissue and urine succinate concentration was determined using a cuvette-based enzymatic assay according to manufacturer's instructions (Boehringer Mannheim/R-Biopharm AG). Briefly, the enzymatic reaction measures the conversion of succinate by succinyl-

**Figure 8**

Changes in whole kidney and serum prorenin content in control and STZ-diabetic *GPR91*^{+/+} and *GPR91*^{-/-} mice. Prorenin was measured in whole kidney homogenates and serum as the difference between renin activity before and after trypsin activation of prorenin measured with a fluorescence renin enzyme assay. Compared to age-matched nondiabetic control animals, prorenin content of both whole kidney tissue and plasma samples increased significantly in diabetic animals. Diabetic *GPR91*^{-/-} animals showed no change in kidney or serum prorenin content. **P* < 0.05, C vs. DM *GPR91*^{+/+}; #*P* < 0.05, DM *GPR91*^{+/+} vs. DM *GPR91*^{-/-} (*n* = 4 each).

CoA synthetase, pyruvate kinase, and L-lactate dehydrogenase and the stoichiometric amount of NADH oxidized in the reaction. By measuring the absorbance at 340 nm (UV detection), the amount of succinate can be calculated from the amount of NADH oxidized. Whole kidney tissue and urine samples were freshly harvested from nondiabetic and diabetic *GPR91*^{+/+} mice. The kidneys of anesthetized, live animals were first flushed with ice-cold PBS injected through the heart and then removed and immediately homogenized on ice in a buffer containing 20 mM Tris-HCL, 1 mM EGTA, pH 7.0, and a protease inhibitor cocktail (BD Biosciences), similar to that described below for western blotting. Urine samples were removed from the bladder and diluted 1:20 with water. Prior to measurements, protein content of kidney homogenates and urine samples was eliminated by using 1 M perchloric acid, which was then neutralized by 2 M KOH. The precipitant was filtered and the pH of the clear solutions was adjusted to 8.5. A reaction solution was combined per kit instructions and incubated with the sample at 37°C for 5 minutes before reading the absorbance of the sample. After 20 minutes of incubation at 37°C, samples were again measured for completion of the assay. The absorbance value was compared against a blank and the concentration was determined.

PGE₂ biosensor technique. Generation of HEK293-EP1 cells as PGE₂ biosensors and their use has been described before (42).

RT-PCR. Total RNA was purified from confluent tsA58 mouse-derived GENC line, afferent arteriolar VSMCs, JG cells, and whole kidney tissue of *GPR91*^{+/+} and *GPR91*^{-/-} mice using a Total RNA Mini kit (Bio-Rad). RNA was quantified using spectrophotometry and reverse-transcribed to single-stranded cDNA using avian reverse-transcriptase and random hexamers according to the manufacturer's instructions (Thermoscript RT-PCR System; Invitrogen). cDNA (2 μl) was amplified using a master mix containing Taq polymerase (Invitrogen) and the following primers: *GPR91* sense, 5'-TGT-GAGAATTGGTTGGCAACAG-3'; *GPR91* antisense, 5'-TCGGTCCATGCTA-ATGACAGT-3', each at a final concentration of 100 μM. The PCR reaction was carried out for 30 cycles of the following: 94°C for 30 seconds, 55.4°C for 30 seconds, and 72°C for 30 seconds. The PCR product was analyzed on a 2% agarose gel to identify *GPR91* fragments of approximately 330 bp.

siRNA interference of *GPR91* in GENCs. On the first day of the study, GENCs were trypsinized, and cells were resuspended at a concentration of 100,000 cells/ml in antibiotic-free complete DMEM medium. Then, 100 μl of cell suspension was added to each well of a 96-well plate and incubated overnight at 37°C with 5% CO₂. The next day, GENCs were transfected employing the protocols validated for the DharmaFECT 1 Transfection Reagent and ON-TARGETplus SMARTpool of 4 *GPR91* siRNAs (Dharmacon). Media were removed from each well of the 96-well plate, and 100 μl of transfection medium was then added to each well. Cells were incubated at 37°C in 5% CO₂ for 48 hours, transferred to larger plates, and then cultured in complete GENC medium for studies. RNA was extracted from cells and amplified to validate inhibition of *GPR91* synthesis. Functional confirmation of *GPR91* knockdown was provided by fluorometric studies on cells. Cells retained adequate *GPR91* silencing for at least 3 passages.

Immunohistochemistry. *GPR91* polyclonal antibody (Millipore) and rat endothelial marker RECA (mouse anti rat RECA-1; AbD Serotec) antibody were used on mouse, rat, and rabbit kidney sections as described before (12, 42). GENCs, VSMCs, and JG renin granular cells on glass coverslips were fixed in 4% formalin for 10 minutes and permeabilized with 0.1% Triton-X in PBS for 5 minutes. Sections were blocked with goat serum (1:20) and incubated overnight with an affinity-purified antibody against the endothelial cell marker CD31 (1:50; Abcam), α-smooth muscle actin (1:400; Sigma-Aldrich), or renin (1:100; a generous gift from T. Inagami, Vanderbilt University, Nashville, Tennessee, USA). This was followed by 1-hour incubation with a AF594- or AF488-conjugated secondary antibody (1:200; Invitrogen). The *GPR91* signal was enhanced with AF594-labeled tyramide signal amplification (TSA) according to the manufacturer's instructions (Invitrogen). Sections were mounted with VECTASHIELD media, containing DAPI for nuclear staining (Vector Laboratories).

Western blot analysis. Manually dissected slices of kidney cortex were homogenized in a buffer containing 20 mM Tris-HCL, 1 mM EGTA, pH 7.0, and a protease inhibitor cocktail (BD Biosciences). Forty micrograms of protein were separated on a 4%–20% SDS-PAGE and transferred onto PVDF membrane. The blots were blocked for a minimum of 1 hour with Odyssey Blocking Buffer (LI-COR Biosciences) at room temperature. This was followed by an incubation of the primary antibody (1:5,000 renin; Fitzgerald) overnight at 4°C, along with β-actin (1:5,000; Abcam) in 2.5 ml 1× PBS (OmniPUR; VWR), 2.5 ml Odyssey Blocking Buffer (LI-COR Biosciences), and 5.0 μl Tween 20 solution (Sigma-Aldrich). After washing with PBS-T, 1× PBS plus 1:1,000 Tween 20, blots were incubated in 2.5 ml PBS, 2.5 ml Blocking Buffer, 5.0 μl Tween 20, and 5.0 μl 10% SDS, with a goat anti-mouse (1:15,000; LI-COR Biosciences) and a goat anti-rabbit secondary antibody (1:15,000; LI-COR Biosciences), and then were visualized with Odyssey Infrared Imaging System, Western Blot Analysis (LI-COR Biosciences).

Trypsinization protocol. Prorenin was evaluated as the difference in renin activity before (active renin) and after trypsinization (total renin). Kidney homogenates were collected from nondiabetic and diabetic mice as described above. Plasma samples were derived from whole blood collected by cardiac puncture and centrifuged for 10 minutes at approximately 3,000 g and -4°C. Trypsinization activates prorenin to renin (43). Samples were trypsinized (50 g/l) for 60 minutes on ice and reaction stopped with Soybean Trypsin Inhibitor (100 g/l) for 10 minutes on ice. Renin activity was evaluated by cuvette-based fluorometry (Quantamaster-8; Photon Technology Inc.) using a FRET-based renin substrate assay as described previously (16). Substrate was present in excess, so the initial reaction rate (within 50 seconds of adding 40 μg sample) estimated renin activity, using Felix software (Photon Technology Inc.). Trypsin in the presence of trypsin inhibitor did not interact with renin substrate.

Spectrofluorometry. [Ca²⁺]_i of GENCs was measured with dual excitation wavelength fluorometry (Quantamaster-8; Photon Technology Inc.) in a



cuvette-based system using the fluorescent probe fura-2. Fura-2 fluorescence was measured at an emission wavelength of 510 nm in response to excitation wavelengths of 340 and 380 nm. Emitted photons were detected by a photomultiplier. Autofluorescence-corrected ratios (340:380) were calculated at a rate of 5 points/sec using Photon Technology Inc. software. GENCs were loaded with fura-2 AM (10 μ M) for 30 minutes. The 340:380 ratios were converted into Ca^{2+} values as described before (44).

In vivo experiments. Male *GPR91^{+/+}* and *GPR91^{-/-}* mice (8–10 weeks of age) were anesthetized using ketamine (50 mg/kg) and inactin (130 mg/kg) and instrumented for multiphoton in vivo imaging of the intact kidney as described before (15, 45). Briefly, the femoral artery was cannulated in order to monitor systemic blood pressure, using an analog single-channel transducer signal conditioner model BP-1 (World Precision Instruments). The left femoral vein was cannulated for infusion of dye, such as quina-crone (Sigma-Aldrich), and rhodamine-conjugated 70,000 MW dextran (Invitrogen). The kidney was exteriorized via a small dorsal incision. The animal was placed on the stage of the Leica IRE2 inverted microscope with the exposed kidney placed in a coverslip-bottomed, heated chamber and the kidney was bathed in normal saline.

Statistics. Data are expressed as mean \pm SEM. Statistical significance was tested using 1-way ANOVA. Significance was accepted at $P < 0.05$.

Acknowledgments

This work was supported by NIH grants DK64324 and DK74754 to J. Peti-Peterdi. I. Toma is a National Kidney Foundation Postdoctoral Fellow. A. Sipos is supported by an American Heart Association Western Affiliate Postdoctoral Fellowship. We thank Amgen for providing breeding pairs of GPR91-knockout mice and M.D. Breyer for providing the HEK293-EP1 biosensor cells, which were developed with support from NIH (DK37097).

Received for publication July 17, 2007, and accepted in revised form April 23, 2008.

Address correspondence to: János Peti-Peterdi, University of Southern California, Zilkha Neurogenetic Institute, 1501 San Pablo Street, ZNI 335, Los Angeles, California 90033, USA. Phone: (323) 442-4337; Fax: (323) 442-4466; E-mail: petipete@usc.edu.

1. Ritz, E., and Dikow, R. 2006. Hypertension and anti-hypertensive treatment of diabetic nephropathy. *Nat. Clin. Pract. Nephrol.* **2**:562–567.
2. Gurley, S.B., and Coffman, T.M. 2007. The renin-angiotensin system and diabetic nephropathy. *Semin. Nephrol.* **27**:144–152.
3. Thomson, S.C., et al. 2001. Ornithine decarboxylase, kidney size, and the tubular hypothesis of glomerular hyperfiltration in experimental diabetes. *J. Clin. Invest.* **107**:217–224.
4. He, W., et al. 2004. Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptors. *Nature.* **429**:188–193.
5. Hebert, S.C. 2004. Physiology: Orphan detectors of metabolism. *Nature.* **429**:143–145.
6. Wittenberger, T., Schaller, H.C., and Hellebrand, S. 2001. An expressed sequence tag (EST) data mining strategy succeeding in the discovery of new G-protein coupled receptors. *J. Mol. Biol.* **307**:799–813.
7. Schnermann, J., and Briggs, J. 1985. Function of the juxtaglomerular apparatus: local control of glomerular hemodynamics. In *The kidney: physiology and pathophysiology*. D.W. Seldin and G. Giebisch, editors. Raven Press. New York, New York, USA. 669–697.
8. Skott, O. 2002. Renin. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* **282**:R937–R939.
9. Francois, H., and Coffman, T.M. 2004. Prostanoids and blood pressure: which way is up? *J. Clin. Invest.* **114**:757–759.
10. Nguyen, G. 2006. Increased cyclooxygenase-2, hyperfiltration, glomerulosclerosis, and diabetic nephropathy: put the blame on the (pro)renin receptor? *Kidney Int.* **70**:618–620.
11. Baumbach, L., Leyssac, P.P., and Skinner, S.L. 1976. Studies on renin release from isolated superfused glomeruli: effects of temperature, urea, ouabain and ethacrynic acid. *J. Physiol.* **258**:243–256.
12. Peti-Peterdi, J., Fintha, A., Fuson, A.L., Tousson, A., and Chow, R.H. 2004. Real-time imaging of renin release in vitro. *Am. J. Physiol. Renal Physiol.* **287**:F329–F335.
13. Toma, I., Kang, J.J., and Peti-Peterdi, J. 2006. Imaging renin content and release in the living kidney. *Nephron Physiol.* **103**:p71–p74.
14. Akis, N., and Madaio, M.P. 2004. Isolation, culture, and characterization of endothelial cells from mouse glomeruli. *Kidney Int.* **65**:2223–2227.
15. Kang, J.J., Toma, I., Sipos, A., McCulloch, F., and Peti-Peterdi, J. 2006. Quantitative imaging of basic functions in renal (patho)physiology. *Am. J. Physiol. Renal Physiol.* **291**:F495–F502.
16. Kang, J.J., Toma, I., Sipos, A., McCulloch, F., and Peti-Peterdi, J. 2006. Imaging the renin-angiotensin system: an important target of anti-hypertensive therapy. *Adv. Drug. Deliv. Rev.* **58**:824–833.
17. Kushnir, M.M., Komaromy-Hiller, G., Shushan, B., Urry, F.M., and Roberts, W.L. 2001. Analysis of dicarboxylic acids by tandem mass spectrometry. High-throughput quantitative measurement of methylmalonic acid in serum, plasma, and urine. *Clin. Chem.* **47**:1993–2002.
18. Schurek, H.J., Jost, U., Baumgardt, H., Bertram, H., and Heckmann, U. 1990. Evidence for a preglomerular oxygen diffusion shunt in rat renal cortex. *Am. J. Physiol.* **259**:F910–F915.
19. Yip, K.P., Holstein-Rathlou, N.H., and Marsh, D.J. 1993. Mechanisms of temporal variation in single-nephron blood flow in rats. *Am. J. Physiol.* **264**:F427–F434.
20. Palm, F. 2006. Intrarenal oxygen in diabetes and a possible link to diabetic nephropathy. *Clin. Exp. Pharmacol. Physiol.* **33**:997–1001.
21. Sadagopan, N., et al. 2007. Circulating succinate is elevated in rodent models of hypertension and metabolic disease. *Am. J. Hypertens.* **20**:1209–1215.
22. Tojo, A., et al. 1994. Immunocytochemical localization of distinct isoforms of nitric oxide synthase in the juxtaglomerular apparatus of normal rat kidney. *J. Am. Soc. Nephrol.* **4**:1438–1447.
23. Khamaisi, M., et al. 2006. Role of renal nitric oxide synthase in diabetic kidney disease during the chronic phase of diabetes. *Nephron Physiol.* **102**:p72–p80.
24. Breyer, M.D., and Harris, R.C. 2001. Cyclooxygenase 2 and the kidney. *Curr. Opin. Nephrol. Hypertens.* **10**:89–98.
25. Cheng, H.F., and Harris, R.C. 2004. Cyclooxygenases, the kidney, and hypertension. *Hypertension.* **43**:525–530.
26. Fiermonte, G., et al. 1999. Organization and sequence of the gene for the human mitochondrial dicarboxylate carrier: evolution of the carrier family. *Biochem J.* **344**:953–960.
27. Markovich, D., and Murer, H. 2004. The SLC13 gene family of sodium sulphate/carboxylate cotransporters. *Pflugers Arch.* **447**:594–602.
28. Sekine, T., Miyazaki, H., and Endou, H. 2006. Molecular physiology of renal organic anion transporters. *Am. J. Physiol. Renal Physiol.* **290**:F251–F261.
29. Scaduto, R.C., Jr., and Schoolwerth, A.C. 1985. Effect of bicarbonate on glutamine and glutamate metabolism by rat kidney cortex mitochondria. *Am. J. Physiol.* **249**:F573–F581.
30. Bogusky, R.T., and Aoki, T.T. 1983. Early events in the initiation of ammonia formation in kidney. *J. Biol. Chem.* **258**:2795–2801.
31. Fine, A. 1989. The effects of fluorocitrate on renal glutamine, lactate, alanine, and oxygen metabolism in the dog. *Can. J. Physiol. Pharmacol.* **67**:641–644.
32. Kurtz, A., and Schweda, F. 2006. Osmolarity-induced renin secretion from kidneys: evidence for readily releasable renin pools. *Am. J. Physiol. Renal Physiol.* **290**:F797–F805.
33. Breyer, M.D., et al. 2005. Mouse models of diabetic nephropathy. *J. Am. Soc. Nephrol.* **16**:27–45.
34. Nguyen, G., et al. 2002. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. *J. Clin. Invest.* **109**:1417–1427.
35. Ichihara, A., et al. 2006. Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice. *J. Am. Soc. Nephrol.* **17**:1950–1961.
36. Takahashi, H., et al. 2007. Regression of nephropathy developed in diabetes by (pro)renin receptor blockade. *J. Am. Soc. Nephrol.* **18**:2054–2061.
37. Peti-Peterdi, J. 2006. Calcium wave of tubuloglomerular feedback. *Am. J. Physiol. Renal Physiol.* **291**:F473–F480.
38. Kovacs, G., et al. 2003. Neuronal nitric oxide synthase: its role and regulation in macula densa cells. *J. Am. Soc. Nephrol.* **14**:2475–2483.
39. Inscho, E.W., Belott, T.P., Mason, M.J., Smith, J.B., and Navar, L.G. 1996. Extracellular ATP increases cytosolic calcium in cultured rat renal arterial smooth muscle cells. *Clin. Exp. Pharmacol. Physiol.* **23**:503–507.
40. Wagner, C.A., et al. 2003. A rapid enzymatic method for the isolation of defined kidney tubule fragments from mouse. *Pflugers Arch.* **446**:623–632.
41. Jensen, B.L., Friis, U.G., and Skott, O. 2003. In vitro studies on renin release. *Methods Mol. Med.* **86**:341–350.
42. Peti-Peterdi, J., et al. 2003. Luminal NaCl delivery regulates basolateral PGE2 release from macula densa cells. *J. Clin. Invest.* **112**:76–82.
43. Suzuki, F., et al. 2000. The dominant role of the prosegment of prorenin in determining the rate of activation by acid or trypsin: studies with molecular chimeras. *Biochem. Biophys. Res. Commun.* **267**:577–580.
44. Peti-Peterdi, J., and Bell, P.D. 1999. Cytosolic [Ca²⁺] signaling pathway in macula densa cells. *Am. J. Physiol.* **277**:F472–F476.
45. Dunn, K.W., et al. 2002. Functional studies of the kidney of living animals using multicolor two-photon microscopy. *Am. J. Physiol. Cell Physiol.* **283**:C905–C916.